Moreover, galunisertib 35 triggers the pyroptotic pathway in glioblastoma, pancreatic cancer, and hepatocellular carcinoma through caspase-1/GSDMD activation [137, 138]. Here, GSDMD is linked to pancreatic neoplasm.